a final rule, advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program, and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC). In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to the CDC. NIOSH implements this responsibility for CDC. The charter was issued on August 3, 2001, renewed at appropriate intervals, rechartered on March 22, 2016 pursuant to Executive Order 13708, and will expire on September 30, 2017.

Purpose: This Advisory Board is charged with (a) providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advising the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class.

Matters To Be Considered: The agenda will include discussions on: Final Vote Counts from the August ABRWH Meeting for Feeds Material Production Center SEC petition (Fernald, OH), Idaho National Laboratory SEC petition (Scoville, ID), and Grand Junction Facilities SEC petition (Grand Junction, CO); Savannah River Site SEC Petition (Aiken, SC); Work Group and Subcommittee Reports; Update on the Status of SEC Petitions; Plans for the December 2017 Advisory Board Meeting; and Advisory Board Correspondence. Agenda items are subject to change as priorities dictate.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Claudette Grant,
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2017–19443 Filed 9–12–17; 8:45 am]

BILLING CODE 4163–19–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**National Center for Health Statistics (NCHS), ICD–10 Coordination and Maintenance (C&M) Committee Meeting**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** The Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD–10 Coordination and Maintenance (C&M) Committee meeting. This meeting is open to the public, limited only by the space available. The meeting room accommodates approximately 240 people. We will be broadcasting the meeting live via Webcast at [http://www.cms.gov/live/](http://www.cms.gov/live/).

**DATES:** The meeting will be held on September 12, 2017, 8:00 a.m. to 5:00 p.m. EDT and September 13, 2017, 8:00 a.m. to 5:00 p.m. EDT.

**ADDRESSES:** Centers for Medicare and Medicaid Services (CMS) Auditorium, 7500 Security Boulevard, Baltimore, Maryland 21244.

**FOR FURTHER INFORMATION CONTACT:** Traci Ramirez, CCA, Program Specialist, CDC, National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff (CPHDSS), 3311 Toledo Rd., Hyattsville, Maryland 20715, telephone (301) 458–4454, tfr4@cdc.gov.

**SUPPLEMENTARY INFORMATION:**

**Purpose:** The ICD–10 Coordination and Maintenance (C&M) Committee is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Tenth Revision, Clinical Modification and ICD–10 Procedure Coding System. Matters To Be Considered: The agenda will include discussions on:

**ICD–10–PCS Topics**
Irreversible Electroporation (IRE)
Shunt Ligation/Occlusion
Spinal Fusion with Interbody Fusion Device
Bypass Descending Thoracic Aorta to Abdominal Artery

**ICD–10–CM Diagnosis Topics**
Anemia due to Myelosuppressive Antineoplastic Chemotherapy
Cyclic Vomiting
Ecstasy Classification
Elevated Lipoprotein(a)
Factual Disorder
Incontinence-Associated Dermatitis (IAD)
Intracranial Hypotension
Muscular Dystrophy
Neonatal Metabolic Disturbances
Other Doubling of Uterus
Primary Sclerosing Cholangitis
Tarlov Perineural Cysts
Williams Syndrome
Zika related newborn conditions

**ICD–10–CM Addendum**

Agenda items are subject to change as priorities dictate.

**Security Considerations:** Due to increased security requirements CMS has instituted stringent procedures for entrance into the building by non-government employees. Attendees will need to present valid government-issued picture identification, and sign-in at the security desk upon entering the building. Attendees who wish to attend the September 12–13, 2017, ICD–10–CM C&M meeting must submit their name and organization by September 8, 2017, for inclusion on the visitor list. This visitor list will be maintained at the front desk of the CMS building and used by the guards to admit visitors to the meeting.

Participants who attended previous Coordination and Maintenance meetings will no longer be automatically added to the visitor list. You must request inclusion of your name prior to each meeting you wish attend.

Please register to attend the meeting on-line at: [http://www.cms.hhs.gov/apps/events/](http://www.cms.hhs.gov/apps/events/).

Please contact Mady Hue (410–786–4510 or Marilu.hue@cms.hhs.gov), for questions about the registration process.

**Note:** CMS and NCHS no longer provide paper copies of handouts for the meeting. Electronic copies of all meeting materials will be posted on the CMS and NCHS Web sites prior to the meeting at [http://www.cms.hhs.gov/ICD9ProviderDiagnosticCodes/03_meetings.asp#TopOfPage](http://www.cms.hhs.gov/ICD9ProviderDiagnosticCodes/03_meetings.asp#TopOfPage) and [https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm](https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm).

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and
Title: Case Plan Requirement, Title IV–E of the Social Security Act.
OMB No.: 0970–0428.
Respondents: State and Tribe title IV–B and title IV–E agencies.
Description: Under section 471(a)(16) of title IV–E of the Social Security Act (the Act), to be eligible for payments, states and tribes must have an approved title IV–E plan that provides for the development of a case plan for each child for whom the State or Tribe receives foster care maintenance payments and that provides a case review system that meets the requirements in section 475(5) and 475(6) of the Act.

The case review system assures that each child has a case plan designed to achieve placement in a safe setting that is the least restrictive (most family-like) setting available and in close proximity to the child’s parental home, consistent with the best interest and special needs of the child. Through these requirements, States and Tribes also comply, in part, with title IV–B section 422(b) of the Act, which assures certain protections for children in foster care.

The case plan is a written document that provides a narrative description of the child-specific program of care. Federal regulations at 45 CFR 1356.21(g) and section 475(1) of the Act delineate the specific information that should be addressed in the case plan. The Administration for Children and Families (ACF) does not specify a recordkeeping format for the case plan nor does ACF require submission of the document to the Federal government. Case plan information is recorded in a format developed and maintained by the State or Tribal child welfare agency.

**ANNUAL BURDEN ESTIMATES**

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average burden hours per response</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case Plan</td>
<td>544,098</td>
<td>1</td>
<td>4.80</td>
<td>2,626,436</td>
</tr>
</tbody>
</table>

Estimated Total Annual Burden Hours: 2,626,436.

In compliance with the requirements of the Paperwork Reduction Act of 1995 (Pub. L. 104–13, 44 U.S.C. Chap 35), the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information may be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 330 C Street SW., Washington, DC 20201. Attn: ACF Reports Clearance Officer. Email address: info@collection@acf.hhs.gov. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Robert Sargis, Reports Clearance Officer.
[FR Doc. 2017–19367 Filed 9–12–17; 8:45 am]
BILLING CODE 4184–25–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

Food and Drug Administration
[Docket No. FDA–2017–D–5297]

Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Microdose Radiopharmaceutical Diagnostic Drugs: Nonclincial Study Recommendations.” This draft guidance is intended to assist developers of microdose radiopharmaceutical diagnostic drugs on the nonclinical studies recommended to support human clinical trials and marketing authorization. The draft guidance discusses how to refine nonclinical study recommendations for this class of drug given its unique characteristics. This draft guidance is intended to provide recommendations for a pathway to full drug development (marketing authorization) for microdose radiopharmaceutical diagnostic drugs.

DATES: Submit either electronic or written comments on the draft guidance by November 13, 2017 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as follows:

Electronic Submissions

Submit electronic comments in the following ways:

• Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that